The EU lacks harmonized regulatory requirements on how investigational medicinal products (IMPs) can be shipped directly to study participants instead of being dispensed at clinical trial sites, but this has not deterred trial sponsors from experimenting with different approaches on this front.
The most commonly deployed model is one with the least regulatory barriers in which the IMP is shipped from the investigative site or the site's pharmacy to the participant's home or other address